COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

Summary

To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen, intubation and mechanical ventilation, or ventilation with additional organ support (e.g., pressors, RRT, ECMO).

Timeline

Start

2020-06-18

Primary completion

2020-12-18

Completion

2021-08-13

Drugs

Indications